Angelica Peebles

Pharma lives to fight another tariff-free day, while staring down the possibility of sector-specific tariffs

RT @l_e_whyte: BREAKING Days after its vaccines chief was pushed out, the FDA is sitting on a decision about Novavax's Covid-19 shot. It ha…

For months, all eyes were on Peter Marks. He was at the top of pretty much everyone's list for key FDA personnel whose departure would shake the industry. Now, he's out. https://t.co/mSfQ493phF

RT @ArmstrongDrew: 🚨 bluebird bio has received a rival takeover bid, worth $45M, from another financial buyer, @maxonwifi scoops https://t…

HHS confirms the changes will result in 3,500 people cut at FDA. Says the reduction "will not affect drug, medical device, or food reviewers, nor will it impact inspectors." https://t.co/3TLRFFQtXc

RT @ArmstrongDrew: Merck is making a deal with China's Hengrui for what drumakers think will be a major new class of cardio medicines, payi…

This week was supposed to mark the end of compounded Zepbound and Mounjaro with the end of the FDA's enforcement discretion, but you can still it online https://t.co/noeUtlcjJx

J&J discontinuing Phase 3 depression drug program. Company says aticaprant showed "insufficient" efficacy https://t.co/fM6kZTkDXM

RT @gerryfsmith: UnitedHealth will cover Vertex's new alternative to opioids, but it may cost more than other painkillers. Scoop w/ @jtozz:…

Novo follows Lilly to introduce its own cash-pay offering for Wegovy https://t.co/CjrEdiK4wy

Lilly CEO Dave Ricks on the today's big manufacturing announcement https://t.co/ztFKoGwlwG

RT @AndrewE_Dunn: My latest dispatch for Post-Hoc, from spending part of last week in DC. The key question: Where is the Roy Vagelos or K…

Bluebird's sale marks a stark reversal for the once high-flying company -- and it's at odds with the transformative results most people see with its treatments https://t.co/gAuMS5ZlPz

Worth noting that Bluebird is selling itself for a fraction of the $80M former CEO Nick Leschly made from selling Bluebird stock

Adam Feuerstein ✡️ @adamfeuerstein

Bluebird Bio $BLUE sells itself to Carlyle, SK Capital for less than $30 million https://t.co/61P4tozPZr via @Jasonmmast Its sale to private equity marks a quiet end for a biotech that, over the course of a dizzying decade, showcased both the power of modern genetic medicine to

A look back at Bluebird as it sells itself to private equity https://t.co/x6SQ3pTcMo

Lilly's Dan Skovronsky weighs in on some of the biggest debates surrounding obesity drugs -- What will it take for new entrants to compete with Zepbound and Wegovy? How much weight do people really need to lose? And more https://t.co/L5gaPpFE8r

PBMs + NBA = 1 Mark Cuban interview https://t.co/11AbNSti0j